-
公开(公告)号:US20050176645A1
公开(公告)日:2005-08-11
申请号:US10953116
申请日:2004-09-30
申请人: Travis Mickle , Suma Krishnan , James Moncrief , Christal Miller , Christopher Lauderback , Thomas Piccariello
发明人: Travis Mickle , Suma Krishnan , James Moncrief , Christal Miller , Christopher Lauderback , Thomas Piccariello
CPC分类号: A61K31/485 , A61K47/549 , A61K47/62
摘要: The present invention decreases the potential for abuse of opioids, particularly hydrocodone, by covalent modification. The invention provides methods of delivering hydrocodone as conjugates that release the hydrocodone following oral administration while being resistant to abuse by circuitous routes such as intravenous (“shooting”) injection and intranasal administration (“snorting”). Further, hydrocodone compositions of the invention are resistant to oral abuse as well, since release of the hydrocodone at suprapharmacological doses reaches saturation.
-
公开(公告)号:US20070060500A1
公开(公告)日:2007-03-15
申请号:US11392878
申请日:2006-03-30
申请人: Travis Mickle , Suma Krishnan , James Moncrief , Christopher Lauderback , Christal Miller , Thomas Piccariello
发明人: Travis Mickle , Suma Krishnan , James Moncrief , Christopher Lauderback , Christal Miller , Thomas Piccariello
IPC分类号: A61K38/17
CPC分类号: A61K31/485 , A61K9/0019 , A61K9/0043 , A61K47/542 , A61K47/64
摘要: The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.
摘要翻译: 本发明涉及药物组合物,其包含以活性剂附着于活性剂的化学部分,其基本上降低了活性剂引起过量或被滥用的潜力。 当以适当剂量递送时,药物组合物提供与母体活性剂类似的治疗活性。
-
公开(公告)号:US20050266070A1
公开(公告)日:2005-12-01
申请号:US10953110
申请日:2004-09-30
摘要: The present invention decreases the potential for abuse of opioids, particularly hydrocodone, by covalent modification. The invention provides methods of delivering hydrocodone as conjugates that release the hydrocodone following oral administration while being resistant to abuse by circuitous routes such as intravenous (“shooting”) injection and intranasal administration (“snorting”). Further, hydrocodone compositions of the invention are resistant to oral abuse as well, since release of the hydrocodone at suprapharmacological doses reaches saturation.
摘要翻译: 本发明通过共价修饰降低了阿片样物质,特别是氢可酮的滥用的可能性。 本发明提供了递送氢可酮作为缀合物的方法,其在口服给药之后释放氢可酮,同时抵抗诸如静脉内(“射击”)注射和鼻内给药(“嗅觉”)等迂回途径的滥用。 此外,本发明的氢可酮组合物也耐口服滥用,因为以超药物剂量的氢可酮的释放达到饱和。
-
公开(公告)号:US20050176646A1
公开(公告)日:2005-08-11
申请号:US10953119
申请日:2004-09-30
IPC分类号: A61K20060101 , A61K38/04 , A61K38/05 , A61K38/06 , A61K38/08
CPC分类号: A61K47/64 , A61K47/542 , A61K47/65
摘要: The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.
摘要翻译: 本发明涉及药物组合物,其包含以活性剂附着于活性剂的化学部分,其基本上降低了活性剂引起过量或被滥用的潜力。 当以适当剂量递送时,药物组合物提供与母体活性剂类似的治疗活性。
-
公开(公告)号:US07338939B2
公开(公告)日:2008-03-04
申请号:US10953110
申请日:2004-09-30
申请人: Travis Mickle , Suma Krishnan , James Scott Moncrief , Christopher Lauderback , Christal Miller
发明人: Travis Mickle , Suma Krishnan , James Scott Moncrief , Christopher Lauderback , Christal Miller
IPC分类号: A61K38/00
摘要: The present invention decreases the potential for abuse of opioids, particularly hydrocodone, by covalent modification. The invention provides methods of delivering hydrocodone as conjugates that release the hydrocodone following oral administration while being resistant to abuse by circuitous routes such as intravenous (“shooting”) injection and intranasal administration (“snorting”). Further, hydrocodone compositions of the invention are resistant to oral abuse as well, since release of the hydrocodone at suprapharmacological doses reaches saturation.
摘要翻译: 本发明通过共价修饰降低了阿片样物质,特别是氢可酮的滥用的可能性。 本发明提供了递送氢可酮作为缀合物的方法,其在口服给药之后释放氢可酮,同时抵抗诸如静脉内(“射击”)注射和鼻内给药(“嗅觉”)等迂回途径的滥用。 此外,本发明的氢可酮组合物也耐口服滥用,因为以超药物剂量的氢可酮的释放达到饱和。
-
-
-
-